II. Indications
III. Contraindications
- Recent major bleeding
IV. Mechanism
- Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
- Inhibits Fibrinogen binding to Platelets
V. Dosing
-
Non-ST elevation Myocardial Infarction (NSTEMI)
- Load: 25 mcg/kg over 5 min
- Infuse: 0.15 mcg/kg/min for up to 18 hours
- Slow rate to 0.075 mcg/kg/min if GFR <=60 ml/min
VI. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
VII. Resources
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C078823 |
SnomedCT | 108981004, 386953003 |
LNC | LP171644-0 |
English | N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine, tirofiban, tirofiban (medication), tirofiban [Chemical/Ingredient], TIROFIBAN, Tirofiban (product), Tirofiban (substance), Tirofiban |
Spanish | tirofibán (producto), tirofibán (sustancia), tirofibán |
Ontology: Aggrastat (C0656369)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C078823 |
English | Aggrastat, aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp & Dohme brand of tirofiban hydrochloride monohydrate, Merck brand of tirofiban hydrochloride monohydrate, Agrastat |